FAQ

pivalyloxymethyl butyrate

Known as: Pivaloyloxymethyl butyrate, Pivaloyloxymethylbutyrate 
An acyloxyalkyl ester prodrug of butyric acid. Pivaloyloxymethylbutyrate inhibits histone deacetylase, resulting in cell differentiation, cell growth… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1991-2016
012319912016

Related topics

Related topics

3 relations

Narrower (2)

AN-9Pivanex

Broader (1)

Butyrates

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
pivalyloxymethyl butyrate
Butyrates
AN-9
Pivanex

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.
Histone modification has emerged as a promising approach to cancer therapy. We explored the in vivo efficacy of a butyric acid… (More)
Is this relevant?
2004
2004
Phase II trial of the histone deacetylase inhibitor pivaloyloxymethyl butyrate (Pivanex, AN-9) in advanced non-small cell lung cancer.
This multicenter phase II trial evaluated the therapeutic activity and safety profile of pivaloyloxymethyl butyrate (Pivanex, AN… (More)
Is this relevant?
2003
2003
Mitoxantrone mediates demethylation and reexpression of cyclin d2, estrogen receptor and 14.3.3sigma in breast cancer cells.
In addition to its action as a topoisomerase II poison, mitoxantrone is activated by formaldehyde to bind DNA, forming DNA… (More)
Is this relevant?
2002
2002
The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines.
The novel prodrug of butyric acid, pivaloyloxymethyl butyrate (AN-9), a histone deacetylase inhibitor, shows great promise as an… (More)
Is this relevant?
2001
2001
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2000
2000
Anticancer derivative of butyric acid (Pivalyloxymethyl butyrate) specifically potentiates the cytotoxicity of doxorubicin and daunorubicin through the suppression of microsomal glycosidic activity.
Pivalyloxymethyl butyrate (AN9) is an anticancer derivative of butyric acid. In this study, doxorubicin (DXR) and AN9… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1998
1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units
The anti-proliferative effects of pivaloyloxymethyl butyrate (AN-9), a butyric acid (BA) derivative with potent tumor… (More)
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
1997
1997
Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells
A novel butyric acid derivative, pivaloyloxymethyl butyrate, AN-9, was previously shown to be a potent differentiating agent. AN… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?
1994
1994
Comparison between the effect of butyric acid and its prodrug pivaloyloxymethylbutyrate on histones hyperacetylation in an HL-60 leukemic cell line.
A butyric acid pro-drug, pivaloyloxymethyl butyrate, AN-9, developed in our laboratory, was previously shown to act as a… (More)
Is this relevant?
1993
1993
Rapid alteration of c-myc and c-jun expression in leukemic cells induced to differentiate by a butyric acid prodrug.
The novel prodrug of butyric acid (BA), pivaloyloxymethyl butyrate, has been shown, in vitro, to induce differentiation and… (More)
Is this relevant?